Tumor-derived semaphorin 4A improves PD-1–blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation

Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice, although the role of human Sema4A in the tumor microenvironment remains unclear. This study demonstrates that histologically Sema4A-positive non–small cell lung cancer (NSCLC) responded significantly better to anti–programmed cell death 1 (PD-1) antibody than Sema4A-negative NSCLC. Intriguingly, SEMA4A expression in human NSCLC was mainly derived from tumor cells and was associated with T cell activation. Sema4A promoted cytotoxicity and proliferation of tumor-specific CD8+ T cells without terminal exhaustion by enhancing mammalian target of rapamycin complex 1 and polyamine synthesis, which led to improved efficacy of PD-1 inhibitors in murine models. Improved T cell activation by recombinant Sema4A was also confirmed using isolated tumor-infiltrating T cells from patients with cancer. Thus, Sema4A might be a promising therapeutic target and biomarker for predicting and promoting ICI efficacy.

[1]  Ansuman T. Satpathy,et al.  Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. , 2022, Cancer cell.

[2]  D. Ito,et al.  IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor Immunity , 2021, The Journal of Immunology.

[3]  T. Aoshi,et al.  Microfluidics sorting enables the isolation of an intact cellular pair complex of CD8+ T cells and antigen-presenting cells in a cognate antigen recognition-dependent manner , 2021, PloS one.

[4]  S. Nada,et al.  The lysosomal Ragulator complex plays an essential role in leukocyte trafficking by activating myosin II , 2021, Nature Communications.

[5]  Hua You,et al.  Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer , 2021, Theranostics.

[6]  Yao Yao,et al.  Semaphorin 4A restricts tumor progression by inhibiting angiogenesis of oral squamous cell carcinoma cells. , 2021, Tissue & cell.

[7]  Yufeng Yao,et al.  De novo synthesis and salvage pathway coordinately regulate polyamine homeostasis and determine T cell proliferation and function , 2020, Science advances.

[8]  G. Ciliberto,et al.  T-cell agonists in cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.

[9]  R. Flavell,et al.  Metabolic signaling in T cells , 2020, Cell Research.

[10]  Jung-Il Lee,et al.  Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma , 2020, Nature Communications.

[11]  E. Wherry,et al.  Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. , 2020, Immunity.

[12]  Nicole M. Chapman,et al.  mTOR signaling at the crossroads of environmental signals and T‐cell fate decisions , 2020, Immunological reviews.

[13]  N. Rizvi,et al.  Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[14]  X. Brannmjk.  Capillary , 2020, Definitions.

[15]  E. Wherry,et al.  Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.

[16]  F. Hodi,et al.  Abstract A83: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2020, Poster Presentations - Proffered Abstracts.

[17]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[18]  A. Keegan,et al.  Semaphorin 4A Stabilizes Human Regulatory T Cell Phenotype via Plexin B1 , 2019, ImmunoHorizons.

[19]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[20]  S. Chapoval,et al.  Neuroimmune Semaphorin 4A in Cancer Angiogenesis and Inflammation: A Promoter or a Suppressor? , 2018, International journal of molecular sciences.

[21]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[22]  M. Tomita,et al.  Metabolomics Platform with Capillary Electrophoresis Coupled with High-Resolution Mass Spectrometry for Plasma Analysis. , 2018, Analytical chemistry.

[23]  B. Nahed,et al.  Sequestration of T-cells in bone marrow in the setting of glioblastoma and other intracranial tumors , 2018, Nature Medicine.

[24]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.

[25]  P. Sly,et al.  Plasmacytoid dendritic cells protect from viral bronchiolitis and asthma through semaphorin 4a–mediated T reg expansion , 2018, The Journal of experimental medicine.

[26]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[27]  G. Freeman,et al.  Interleukin‐17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD‐1 Blockade , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  C. Cordon-Cardo,et al.  mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer , 2017, Nature.

[29]  J. Borg,et al.  A reverse signaling pathway downstream of Sema4A controls cell migration via Scrib , 2017, The Journal of cell biology.

[30]  D. Ito,et al.  The role of Sema4A in angiogenesis, immune responses, carcinogenesis, and retinal systems , 2016, Cell adhesion & migration.

[31]  G. Freeman,et al.  Coinhibitory Pathways in Immunotherapy for Cancer. , 2016, Annual review of immunology.

[32]  Greg M. Delgoffe,et al.  Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8 T cell differentiation , 2016, Nature Immunology.

[33]  Masahiro Yamamoto,et al.  mTOR Complex Signaling through the SEMA4A–Plexin B2 Axis Is Required for Optimal Activation and Differentiation of CD8+ T Cells , 2015, The Journal of Immunology.

[34]  M. Büchler,et al.  Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice , 2015, International journal of cancer.

[35]  Clare L. Bennett,et al.  OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence , 2015, The Journal of Immunology.

[36]  Hajime Sato,et al.  Statistical hypothesis testing of factor loading in principal component analysis and its application to metabolite set enrichment analysis , 2014, BMC Bioinformatics.

[37]  David K. Finlay,et al.  PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells , 2012, The Journal of experimental medicine.

[38]  A. Kumanogoh,et al.  Diverse roles for semaphorin-plexin signaling in the immune system. , 2012, Trends in immunology.

[39]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[40]  Y. Oda,et al.  A shift of the TOR adaptor from Rictor towards Raptor by semaphorin in C. elegans , 2011, Nature communications.

[41]  G. Freeman,et al.  4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection , 2011, The Journal of Immunology.

[42]  M. Tomita,et al.  Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles , 2009, Metabolomics.

[43]  Falk Schreiber,et al.  VANTED: A system for advanced data analysis and visualization in the context of biological networks , 2006, BMC Bioinformatics.

[44]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[45]  S. Akira,et al.  Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. , 2005, Immunity.

[46]  T. Aoshi,et al.  Expression mapping using a retroviral vector for CD8+ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by H2-Dd. , 2005, Journal of immunological methods.

[47]  Toshihiro Ito,et al.  Expression of recombination-activating gene in mature peripheral T cells in Peyer's patch. , 2003, International immunology.

[48]  S. Sakoda,et al.  Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2 , 2002, Nature.

[49]  G. Babcock,et al.  Intracellular polyamine biosynthesis is required for interleukin 2 responsiveness during lymphocyte mitogenesis. , 1987, Cellular immunology.

[50]  Greg M. Delgoffe,et al.  mTORC 1 and mTORC 2 selectively regulate CD 8 + T cell differentiation , 2018 .

[51]  H. Hermeking,et al.  Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis. , 2017, Cancer research.

[52]  R. Gold,et al.  Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. , 2016, Immunity.